Patents Assigned to ChemoCentryx, Inc.
-
Publication number: 20240132495Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula I including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: November 29, 2023Publication date: April 25, 2024Applicant: CHEMOCENTRYX, INC.Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
-
Patent number: 11951214Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.Type: GrantFiled: December 8, 2021Date of Patent: April 9, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Manmohan Reddy Leleti, Jay P. Powers
-
Patent number: 11945805Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:Type: GrantFiled: April 29, 2021Date of Patent: April 2, 2024Assignee: CHEMOCENTRYX, INCInventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
-
Publication number: 20240100041Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.Type: ApplicationFiled: December 6, 2023Publication date: March 28, 2024Applicant: CHEMOCENTRYX, INC.Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
-
Patent number: 11890276Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.Type: GrantFiled: August 23, 2021Date of Patent: February 6, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
-
Patent number: 11884654Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.Type: GrantFiled: September 9, 2021Date of Patent: January 30, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
-
Patent number: 11883391Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.Type: GrantFiled: March 31, 2021Date of Patent: January 30, 2024Assignee: CHEMOCENTRYX, INC.Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
-
Patent number: 11872217Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.Type: GrantFiled: July 9, 2020Date of Patent: January 16, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11866429Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 15, 2020Date of Patent: January 9, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
-
Patent number: 11845729Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.Type: GrantFiled: February 8, 2022Date of Patent: December 19, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
-
Patent number: 11844790Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).Type: GrantFiled: October 27, 2021Date of Patent: December 19, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Shijie Li, Rajinder Singh, Thomas J. Schall, Peter Staehr
-
Patent number: 11834452Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: GrantFiled: May 27, 2021Date of Patent: December 5, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
-
Patent number: 11820759Abstract: Compounds are provided as chemokine inhibitors having the structure:Type: GrantFiled: March 4, 2021Date of Patent: November 21, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
-
Patent number: 11807609Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 9, 2020Date of Patent: November 7, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Pingchen Fan, Rebecca M. Lui, Venkat Reddy Mali, Rajinder Singh, Yibin Zeng, Penglie Zhang
-
Patent number: 11793771Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: June 13, 2022Date of Patent: October 24, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11779576Abstract: Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.Type: GrantFiled: February 14, 2022Date of Patent: October 10, 2023Assignee: CHEMOCENTRYX, INC.Inventor: Petrus Bekker
-
Patent number: 11773091Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.Type: GrantFiled: May 3, 2022Date of Patent: October 3, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
-
Patent number: 11759458Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: August 30, 2021Date of Patent: September 19, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
-
Patent number: 11759454Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: GrantFiled: July 8, 2020Date of Patent: September 19, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Xi Chen, Pingchen Fan, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang, Dean Dragoli
-
Patent number: 11744822Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.Type: GrantFiled: January 14, 2020Date of Patent: September 5, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Israel Charo, Heiyoun Jung, Thomas J. Schall, Penglie Zhang
